Prevention Of Stroke In Nonvalvular Atrial Fibrillation
Key Points
Key Points
- The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
- The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
- For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
- The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.
Diagnosis
...gnosis...
...e Risk in Patients With Nonvalvular...
...1. Patterns of Atrial Fibrillation...
Treatment
...eatment...
...arin (A)300167...
...gatran (B)30016...
...xaban (B)300167...
...ivaroxaban (B)3001...
...afety and efficacy of combining dabigatr...
...irin, Clopidogrel & Warfari...
...djusted-dose warfarin (target INR â...
Antiplatelet therapy with aspirin is r...
...atients with AF deemed unsuitable for antic...
...h ischemic stroke or TIA with paroxysmal (interm...
...ble to take oral anticoagulants, aspirin...
...on of clopidogrel plus aspirin carries...
...bigatran...
...n is useful as an alternative to warfari...
...an 150 mg twice daily is an efficacious...
...is of pharmacokinetic data, the us...
...ause there are no data to support the use of dab...
...pixaba...
...twice daily is an efficacious alte...
Although its safety and efficacy have not been...
...5 mg twice daily is a relatively safe...
...afety and efficacy have not been established, a...
...ould NOT be used if the CrCI is
...varoxaban
...nts with nonvalvular AF who are at moder...
...with renal impairment and nonvalvular AF w...
...xaban should NOT be used if the CrCI is...
...2. Agents Recommended for Stroke Preventio...
...2. Prevention of Stroke in Nonvalvula...